The diurnal variation of matrix metalloproteinase-9 and its associated factors in human tears

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 3, 2012, Pages 1479-1484

  Markoulli, Maria ^a,b   Papas, Eric ^a,b,c   Cole, Nerida ^a,b,c   Holden, Brien A ^a,b,c  

^a BRIEN HOLDEN VISION INSTITUTE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c VISION COOPERATIVE RESEARCH CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ADULT; AROUSAL; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LACRIMAL FLUID; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CONTENT; VISUAL ACUITY; WAKEFULNESS; ZYMOGRAPHY; ADOLESCENT; ANALYSIS OF VARIANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; REPRODUCIBILITY;

ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CIRCADIAN RHYTHM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOCALINS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; REPRODUCIBILITY OF RESULTS; TEARS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; YOUNG ADULT;

EID: 84860579435     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8365     Document Type: Article

References (44)

1. Sivak JM, Fini ME. MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res. 2002; 21:1-14.
2. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516.
3. Di Girolamo N, Indoh I, Jackson N, et al. Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: role in cell migration. J Immunol. 2006;177:2638-2650.
4. Snoek-van Beurden PA, Von den Hoff JW. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. BioTechniques. 2005;38:73-83.
5. Parks WC, Mecham RP, eds. Matrix Metalloproteinases. 1st ed. San Diego: Academic Press; 1998.
6. Fini ME, Girard MT. Expression of collagenolytic/gelatinolytic metalloproteinases by normal cornea. Invest Ophthalmol Vis Sci. 1990;31:1779-1788.
7. Sack RA, Sathe S, Beaton AR, Bogart B, Lew G. Changes in the diurnal pattern of the distribution of gelatinases and associated proteins in normal and pathological tear fluids: evidence that the PMN cell is a major source of MMP activity in tear fluid. Adv Exp Med Biol. 2002;506:539-545.
8. Leonardi A, Brun P, Abatangelo G, Plebani M, Secchi A. Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis. Invest Ophthalmol Vis Sci. 2003;44: 3052-3058.
9. Sobrin L, Liu Z, Monroy DC, et al. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci. 2000;41:1703-1709.
10. Afonso AA, Sobrin L, Monroy DC, Selzer M, Lokeshwar B, Pflugfelder SC. Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci. 1999;40:2506-2512.
11. Garrana RMR, Zieske JD, Assouline M, Gipson RK. Matrix metalloproteinases in epithelia from human recurrent corneal erosion. Invest Ophthalmol Vis Sci. 1999;40:1266-1270.
12. Fini ME, Cook JR, Mohan R. Proteolytic mechanisms in corneal ulceration and repair. Arch Dermatol Res. 1998;290(suppl):S12-S23.
13. Smith VA, Rishmawi H, Hussein H, Easty DL. Tear film MMP accumulation and corneal disease. Br J Ophthalmol. 2001;85:147-153.
14. Di Girolamo N, Wakefield D, Coroneo MT. Differential expression of matrix metalloproteinases and their tissue inhibitors at the advancing pterygium head. Invest Ophthalmol Vis Sci. 2000;41: 4142-4149.
15. Matsubara M, Girard MT, Kublin CL, Cintron C, Fini ME. Differential roles for two gelatinolytic enzymes of the matrix metalloproteinase family in the remodelling cornea. Dev Biol. 1991;147:425-439.
16. Daniels JT, Geerling G, Alexander RA, Murphy G, Khaw PT, Saarialho-Kere U. Temporal and spatial expression of matrix metalloproteinases during wound healing of human corneal tissue. Exp Eye Res. 2003;77:653-664.
17. Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004;432:917-921.
18. Devarajan P. Review: neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Nephrology. 2010;15:419-428.
19. Roudkenar MH, Halabian R, Bahmani P, Roushandeh AM, Kuwahara Y, Fukumoto M. Neutrophil gelatinase-associated lipocalin: a new antioxidant that exerts its cytoprotective effect independent on Heme Oxygenase-1. Free Radic Res. 2011;45:810-819.
20. Ehrmann K, Fedtke C, Radic A. Assessment of computer generated vision charts. Cont Lens Anterior Eye. 2009;32:133-140.
21. CCLRU. Cornea and Contact Lens Research Unit. C.C.L.R.U. Grading Scales. Sydney, Australia: University of New South Wales; 1996.
22. Markoulli M, Papas E, Petznick A, Holden B. Validation of the flush method as an alternative to basal or reflex tear Collection. Curr Eye Res. 2011;36:198-207.
23. German EJ, Hurst MA, Wood D. Reliability of drop size from multi-dose eye drop bottles: is it cause for concern? Eye (Lond). 1999;13:93-100.
24. Sack RA, Tan KO, Tan A. Diurnal tear cycle: evidence for a nocturnal inflammatory constitutive tear fluid. Invest Ophthalmol Vis Sci. 1992;33:626-640.
25. Petznick A, Evans MD, Madigan MC, Markoulli M, Garrett Q, Sweeney DF. A comparison of basal and eye-flush tears for the analysis of cat tear proteins. Acta Ophthalmol. 2011;89:e75-81.
26. Shapiro SD, Fliszar CJ, Broekelmann TJ, Mecham RP, Senior RM, Welgus HG. Activation of the 92-kDa gelatinase by stromelysin and 4-aminophenylmercuric acetate. J Biol Chem. 1995;270:6351-6356.
27. Hawkes SP, Li H, Taniguchi GT. Zymography and reverse zymography for detecting MMPs, and TIMPs. Methods Mol Biol. 2001; 151:399-410.
28. Institution BS. Precision of Test Methods, Part 1: Guide for the Determination of Repeatability and Reproducibility for a Standard Test Method. BS 5497, Part 1. London: BSI; 1979.
29. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1: 307-310.
30. Roy R, Louis G, Loughlin KR, et al. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res. 2008;14:6610-6617.
31. Barro CD, Romanet JP, Fdili A, Guillot M, Morel F. Gelatinase concentration in tears of corneal-grafted patients. Curr Eye Res. 1998;17:174-182.
32. Kumagai N, Yamamoto K, Fukuda K, et al. Active matrix metalloproteinases in the tear fluid of individuals with vernal keratoconjunctivitis. J Allergy Clin Immunol. 2002;110:489-491.
33. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993;268:10425-10432.
34. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
35. Brown N, Bron A. Recurrent erosion of the cornea. Br J Ophthalmol. 1976;60:84-96.
36. Dua HS. Recurrent corneal erosion syndrome. Surv Ophthalmol. 2008;53:664; author reply 664-665.
37. Willcox MD, Naduvilath TJ, Vaddavalli PK, Holden BA, Ozkan J, Zhu H. Corneal erosions, bacterial contamination of contact lenses, and microbial keratitis. Eye Contact Lens. 2010;36:340-345.
38. Stapleton F, Keay L, Edwards K, et al. The incidence of contact lens-related microbial keratitis in Australia. Ophthalmology. 2008; 115:1655-1662.
39. Kernacki KA, Barrett R, Hazlett LD. Evidence for TIMP-1 protection against P. aeruginosa-induced corneal ulceration and perforation. Invest Ophthalmol Vis Sci. 1999;40:3168-3176.
40. Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukahara S, Lindsey JD. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997; 38:2772-2780.
41. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci. 1997;38:2214-2223.
42. Honda N, Miyai T, Nejima R, et al. Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface. Arch Ophthalmol. 2010;128:466-471.
43. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490-496.
44. Costagliola C, Del Prete A, Verolino M, et al. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients. Graefes Arch Clin Exp Ophthalmol. 2002;240:379-386.